Individual ingredients of NP-101 (Thymoquinone formula) inhibit SARS-CoV-2 pseudovirus infection
Copyright © 2024 Maen, Gok Yavuz, Mohamed, Esmail, Lu, Mohamed, Azmi, Kaseb, Kasseb, Li, Gocio, Kocak, Selim, Ma and Kaseb..
Thymoquinone TQ, an active ingredient of Nigella Sativa, has been shown to inhibit COVID-19 symptoms in clinical trials. Thymoquinone Formulation (TQF or NP-101) is developed as a novel enteric-coated medication derivative from Nigella Sativa. TQF consists of TQ with a favorable concentration and fatty acids, including palmitic, oleic, and linoleic acids. In this study, we aimed to investigate the roles of individual ingredients of TQF on infection of SARS-CoV-2 variants in-vitro, by utilizing Murine Leukemia Virus (MLV) based pseudovirus particles. We demonstrated that NP-101, TQ, and other individual ingredients, including oleic, linoleic, and palmitic acids inhibited SARS-CoV-2 infection in the MLV-based pseudovirus model. A large, randomized phase 2 study of NP-101 is planned in outpatient COVID-19 patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Frontiers in pharmacology - 15(2024) vom: 19., Seite 1291212 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Maen, Abdelrahim [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Revised 22.02.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3389/fphar.2024.1291212 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368699315 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368699315 | ||
| 003 | DE-627 | ||
| 005 | 20240222232832.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240222s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fphar.2024.1291212 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1302.xml |
| 035 | |a (DE-627)NLM368699315 | ||
| 035 | |a (NLM)38379905 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Maen, Abdelrahim |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Individual ingredients of NP-101 (Thymoquinone formula) inhibit SARS-CoV-2 pseudovirus infection |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 22.02.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2024 Maen, Gok Yavuz, Mohamed, Esmail, Lu, Mohamed, Azmi, Kaseb, Kasseb, Li, Gocio, Kocak, Selim, Ma and Kaseb. | ||
| 520 | |a Thymoquinone TQ, an active ingredient of Nigella Sativa, has been shown to inhibit COVID-19 symptoms in clinical trials. Thymoquinone Formulation (TQF or NP-101) is developed as a novel enteric-coated medication derivative from Nigella Sativa. TQF consists of TQ with a favorable concentration and fatty acids, including palmitic, oleic, and linoleic acids. In this study, we aimed to investigate the roles of individual ingredients of TQF on infection of SARS-CoV-2 variants in-vitro, by utilizing Murine Leukemia Virus (MLV) based pseudovirus particles. We demonstrated that NP-101, TQ, and other individual ingredients, including oleic, linoleic, and palmitic acids inhibited SARS-CoV-2 infection in the MLV-based pseudovirus model. A large, randomized phase 2 study of NP-101 is planned in outpatient COVID-19 patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a COVID-19 and anti-viral agents | |
| 650 | 4 | |a Coronavirus | |
| 650 | 4 | |a TQ formula | |
| 650 | 4 | |a Thymoquinone TQ | |
| 650 | 4 | |a fatty acids | |
| 700 | 1 | |a Gok Yavuz, Betul |e verfasserin |4 aut | |
| 700 | 1 | |a Mohamed, Yehia I |e verfasserin |4 aut | |
| 700 | 1 | |a Esmail, Abdullah |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Jianming |e verfasserin |4 aut | |
| 700 | 1 | |a Mohamed, Amr |e verfasserin |4 aut | |
| 700 | 1 | |a Azmi, Asfar S |e verfasserin |4 aut | |
| 700 | 1 | |a Kaseb, Mohamed |e verfasserin |4 aut | |
| 700 | 1 | |a Kasseb, Osama |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Dan |e verfasserin |4 aut | |
| 700 | 1 | |a Gocio, Michelle |e verfasserin |4 aut | |
| 700 | 1 | |a Kocak, Mehmet |e verfasserin |4 aut | |
| 700 | 1 | |a Selim, Abdelhafez |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, Qing |e verfasserin |4 aut | |
| 700 | 1 | |a Kaseb, Ahmed O |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in pharmacology |d 2010 |g 15(2024) vom: 19., Seite 1291212 |w (DE-627)NLM208568891 |x 1663-9812 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2024 |g day:19 |g pages:1291212 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fphar.2024.1291212 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2024 |b 19 |h 1291212 | ||